LONGBIO-B (01779.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 9.61B

MomentumView details →

1D Return

+4.07%

YTD Return

—

RSI (14)

57.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 9.61B

RSI (14)

57.9

MomentumView details →

1D Return

+4.07%

YTD Return

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Latest newsMore news →

Tianchen Biopharmaceutical announced its interim results for the six months ended June 2026, reporting a net loss of RMB 135 million, wider than the RMB 94.208 million loss in the same period last year, with a loss per share of RMB 2.18 and no dividend.15d ago

Tianchen Biopharmaceutical-B announced that its self-developed anti-IgE antibody LP-003 for seasonal allergic rhinitis has had its Biologics License Application accepted by China's National Medical Products Administration.16d ago

Similar companies

Ionis Pharmaceuticals, Inc.IONS GenFleet Therapeutics (Shanghai) Inc.02595.HK Kymera Therapeutics, Inc.KYMR Protagonist Therapeutics, Inc.PTGX Nuvalent, Inc.NUVL Ascletis Pharma Inc.01672.HK Find similar companies →

Latest newsMore news →

Tianchen Biopharmaceutical announced its interim results for the six months ended June 2026, reporting a net loss of RMB 135 million, wider than the RMB 94.208 million loss in the same period last year, with a loss per share of RMB 2.18 and no dividend.15d ago Tianchen Biopharmaceutical-B announced that its self-developed anti-IgE antibody LP-003 for seasonal allergic rhinitis has had its Biologics License Application accepted by China's National Medical Products Administration.16d ago